Please Wait...

MMP-9 // Active and Pro-Matrix Metalloproteinase 9

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

The MMPs family comprises at least 24 different MMPs with high sequence similarity in their catalytic domains. MMPs are synthetized as pro-enzymes which are inactive until removal of their pro-domain (Löffek et al., 2011; Nagase and Woessner, 1999). MMP-9 is also called gelatinase B and its expression is induced by numerous factors including TGF-β, TNF-α and VEGF. MMP-9 degrades denatured collagens, matrix associated substrate, aggrecan and can also convert some cytokines into more active or inactive immune signals (Vandooren et al., 2013). MMP-9 is implicated in a wide variety of processes and dysregulation of its production have been linked to several pathologies such as inflammatory, cardiovascular, muscle and bone diseases and cancer (Vandooren et al., 2013).

Bioclinica Lab employs a manual sandwich immunoassay for the measurement of total MMP-9 in serum.

ADDITIONAL RESOURCES

Biomarker Menu

Download MENU

Molecular Marker Laboratory Services

Download Brochure

Alzheimer's Disease Biomarker Lab Expertise

Download Info Sheet

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

We're hiring recent tech grads in #RTP for #pharma sector! Our innov. clinical financial solution gives our client… https://t.co/GHgOfszO0T
bioclinica (3 hours ago)
Great to be @DrugInfoAssn DIA China! Ask us @bioclinica how sponsors & CROs can optimize electronic data capture… https://t.co/TtE4AiLnqY
bioclinica (9 hours ago)
RT @bioclinica: Kinks in the clinical supply chain? Check out how one of our clients is using clinical supply optimization technology for m…
bioclinica (9 hours ago)
RT @bioclinica: Welcoming everyone to KOP for #OCTEast Coast!!
bioclinica (9 hours ago)
Welcoming everyone to KOP for #OCTEast Coast!!
bioclinica (Yesterday)
Case processing is an important aspect of post-marketing drug safety surveillance. Here's a case study showing how… https://t.co/UMYp92Puvc
bioclinica (2 days ago)

Latest Blogs:

Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen